Mondrian Investment Partners 13F: Adds $30M to Zoetis (ZTS) Stake

Mondrian Investment Partners significantly expanded its holdings in Zoetis Inc. ZTS, according to a Form 13F filing with the SEC on October 23, 2026. The institutional investor added 434,964 shares during the period, representing a 172.8% increase from the prior quarter. That brought the firm's total stake to 686,672 shares, with a reported value of $47,950,306.

ZTS Zoetis Inc.

$82 ▼ -33.86% year to date

1M 3M YTD

Daily close · Oct 22, 2026

What Changed in Mondrian Investment Partners's Zoetis Inc. Position

The substantial addition lifted the firm's share count from 251,708 shares up to 686,672 shares. Mondrian Investment Partners did not open a brand-new position or exit its existing holding, but rather chose to dramatically scale up its investment in the animal health specialist during the period.

Other Institutional Activity in Zoetis Inc.

Other large money managers also adjusted their positions in the stock. Moran Wealth Management grew its holdings by 35,213 shares, ending with 445,975 shares worth about $31,142,424. Fideuram - Intesa Sanpaolo Private Banking S.P.A. lifted its stake by 101,852 shares, bringing its total to 265,022 shares valued at $18,506,492. Midwest Trust reduced its holdings by 114,689 shares, ending with 9,372 shares worth about $654,447. Fifth Third Wealth Advisors grew its holdings by 12,137 shares, ending with 49,817 shares worth about $3,478,751. State Farm Mutual Automobile Insurance Co kept its position steady at 15,892,903 shares valued at $1,287,801,910.

Zoetis Inc. Stock Up 1.7%

Zoetis Inc. recently traded around $81.00 as of October 24, 2026, roughly equal to its closing price of $81.03 on the filing date. The stock trades about 8.8% above its 50-day moving average of $74.48, but remains roughly 14.7% below its 200-day moving average of $94.92. Over the past year, shares have moved between a low of $68.77 and a high of $147.93, leaving the recent price about 45.2% below its 52-week peak. The consensus analyst price target stands at $93.00, meaning the recent price sits roughly 12.9% below that average goal.

Recent Earnings

Zoetis Inc. generated $9,525,000,192 in trailing-twelve-month revenue alongside basic earnings of $6.26 per share. The company reported a net profit margin of 27.7% and a return on equity of 64.9%. The next quarterly earnings report is scheduled for November 5, 2026.

Dividend

The company distributes an annual dividend rate of $2.12 per share, translating to a dividend yield of 2.59%. The payout ratio sits at 33.9% of earnings.

Insider Buying and Selling at Zoetis Inc.

Company insiders made several purchases earlier in the year prior to the filing. Director Michael B. McCallister bought 3,000 shares on May 11, 2026, at an average price of $77.76 for a total of $233,273. Director Frank A. D. Amelio acquired 6,650 shares on May 13, 2026, at $75.39 per share, totaling $501,344. Director Paul M. Bisaro picked up 2,000 shares on May 13, 2026, at $75.88 per share for a total of $151,750.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock through late summer and autumn. Citigroup maintained a Buy rating on August 11, 2026, while lowering its target from $112.00 to $96.00. Stifel maintained a Hold rating on August 20, 2026, adjusting its target from $85.00 to $80.00. TD Cowen maintained a Buy rating on August 25, 2026, moving its target from $104.00 to $94.00. Goldman Sachs initiated coverage with a Neutral rating and a $74.00 target on October 16, 2026. Jefferies downgraded the stock to Hold on October 20, 2026, cutting its target from $103.00 to $83.00. Overall, the stock carries a consensus buy recommendation from 14 analysts.

About Zoetis Inc.

Zoetis Inc. develops and manufactures medicines, vaccines, and diagnostic products for both companion animals like dogs, cats, and horses, and livestock species such as cattle, swine, and poultry. Based in Parsippany, New Jersey, the company serves veterinarians, livestock producers, and pet owners worldwide. Institutional interest from large firms highlights ongoing portfolio adjustments ahead of upcoming earnings announcements.

Bottom Line

Investors are keeping a close watch on Zoetis Inc. as the company prepares to release its next financial update on November 5, 2026. Future 13F filings will show whether institutional backers continue to expand or trim their positions following recent market shifts.